Meeting to be held in New York on April 29 hosted by Truist.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp’s Potential in Treating Friedreich’s Ataxia
- Promising Developments and Financial Strength Support Buy Rating for Larimar Therapeutics
- Larimar Therapeutics should be bought on weakness, says Citi
- Larimar Therapeutics price target raised to $16 from $15 at H.C. Wainwright
- Larimar Therapeutics price target lowered to $10 from $13 at Baird